Going Out With a Bang--An Interview with Ron Dollens
Few companies have achieved the kinds of success that Guidant Corp. has in its ten years in existence and few executives have had the impact on the medical device space that Ron Dollens, Guidant's CEO, has had. In this interview, adapted from the Stanford BioDesign Program's "From the Innovator's Work Bench" series, Dollens talks about his career and about the success Guidant has had.
You may also be interested in...
In a career that has spanned more than 20 years, Bill Hawkins has worked for a wide array of medical device firms, leaving his imprint on this industry. Now, as Medtronic's COO, his influence will only grow. In this interview, Hawkins talks about the history of the device industry and what lies ahead.
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.